You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

318 Results
Cette plateforme contient des outils et des ressources pour les prestataires de soins primaires, les colposcopistes et d’autres professionnels de la...
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative, Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
Jan 2026
Guidelines and Advice
Updated
Jan 2026
La trousse SEER*Stat du Registre des cas de cancer de l’Ontario contient des fichiers de données anonymisées sur le cancer en Ontario extraits du...
Guidelines and Advice
Status: In-Review
ID: 17-1
Version: 2
Mar 2015
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Intent: Palliative
Feb 2026
Drug
Other Name(s): Zoladex® , Zoladex® LA
Mar 2026
Regimen
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    goserelin
Mar 2026
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Tebentafusp (Outpatient) - Unresectable or Metastatic Uveal Melanoma
High Cost Therapy Funding Program
    Tebentafusp (Inpatient) - Unresectable or Metastatic Uveal Melanoma
Mar 2026
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Teclistamab (Outpatient) - Relapsed or Refractory Multiple Myeloma
High Cost Therapy Funding Program
    Teclistamab (Inpatient) - Relapsed or Refractory Multiple Myeloma
Mar 2026

Pages